Evidence map›Paper›PMID 41688920›Full record

ArticleBMC infectious diseases2026

Mpox comprehensive assessment for responsive immunisation in emergency outbreaks (MpoxCARE): study protocol.

Karishma Gokani, Herve Semukunzi, Gilbert Rukundo, Jenny Clarke, Sian E Faustini, Jean Pierre Musabyimana, Siobhan Roche, Scott Jones, Ashley David Otter, Alex Richter and 4 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06887556 (Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06887556 narecruitingnot on this map

Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks

TypeinterventionalSponsorUniversity of BirminghamRan2025 to 2026Enrolled650ConditionsMpoxArmsELISA, Lateral flow assay
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Karishma Gokani *School of Chemical Engineering, University of Birmingham, Birmingham, UK. k.gokani@bham.ac.uk.
Herve Semukunzi *School of Chemical Engineering, University of Birmingham, Birmingham, UK.
Gilbert RukundoSchool of Chemical Engineering, University of Birmingham, Birmingham, UK.
Jenny ClarkeSchool of Chemical Engineering, University of Birmingham, Birmingham, UK.
Sian E FaustiniClinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Jean Pierre MusabyimanaRwanda Biomedical Centre, Kigali, Rwanda.
Siobhan RocheSchool of Chemical Engineering, University of Birmingham, Birmingham, UK.
Scott JonesEmerging Pathogen Serology Group, Vaccine Development and Evaluation Centre (VDEC), UK Health Security Agency, Porton Down, UK.
Ashley David OtterEmerging Pathogen Serology Group, Vaccine Development and Evaluation Centre (VDEC), UK Health Security Agency, Porton Down, UK.
Alex RichterClinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Claude MuvunyiRwanda Biomedical Centre, Kigali, Rwanda.
Jennifer Heaney *Clinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Christopher Aird Green *School of Chemical Engineering, University of Birmingham, Birmingham, UK.
MpoxCARE Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMpox disease is endemic to several regions of sub-Saharan Africa, with transmission occurring through close contact with infected animals or humans. Increasing case numbers in East Africa led the African Centre for Disease Control and Prevention to declare a Public Health Emergency of Continental Security on 13th August 2024 related to a new virus variant (clade 1b). The Mpox CARE study aims to establish clinical and epidemiology data to develop innovative immunodiagnostic tests, facilitating models for sub-clinical disease exposure, transmission and future vaccine strategies (Part A). Furthermore, we aim to evaluate and optimize vaccine cold-chain (VCC) systems to support Mpox vaccine deployment while ensuring the continued provision of childhood immunizations (Part B).

methodsThis study will recruit up to 650 participants to three study groups according to Mpox exposure status and/or vaccination in Rwanda. All enrolled participants will be asked to provide demographic information, relevant medical history, up to 20mLs of venous blood and a dried blood spot capillary blood sample. For Part A of the study, samples will undergo testing for quantitative analysis of total serum antibody to Mpox specific proteins using an enzyme-linked immunosorbent assay (ELISA) and test a novel point-of-care (POC) lateral flow test to determine positive/negative qualitative serostatus. For Part B, we will collect data on VCC equipment, inventories and methods of vaccine distribution. The results of this project aim to (a) validate a blood-based ELISA assay for the detection of Mpox immunity in a target population of Rwanda, (b) generate an estimate of sero-positivity to Mpox in Rwanda, (c) evaluate the clinical performance of a novel POC lateral flow test for Mpox serostatus and (d) understand the VCC requirements for additional vaccine deployment for disease control. DISCUSSION: Detecting antibodies for sub-clinical Mpox cases improves disease mapping and transmission patterns in endemic African regions. Novel POC immunodiagnostics can enhance community healthcare and decentralise efforts to understand Mpox seroepidemiology. Understanding VCC requirements for deployment of genetic vaccines, alongside regular vaccine provision to pregnant women, and children offers insights for management of future vaccine-preventable disease outbreaks. TRAIL REGISTRATION: Clinicaltrials.gov trial registration number NCT06887556, registered 20th March 2025.

Indexed as

Disease OutbreaksMonkeypox virusMpox, MonkeypoxViral VaccinesAntibodies, ViralClinical Laboratory TechniquesClinical Trials as TopicEnzyme-Linked Immunosorbent AssayFemaleHumansMaleRefrigerationRwandaVaccinationAntibodies, ViralViral VaccinesCold-chainImmune diagnosticMpoxOutbreakSeroepidemiologyVaccine

Identifiers

PMID41688920
PMCPMC13005514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.